Animal Models of Human Diseases: Preclinical Research Services for Drug Development & Mechanistic Studies

As an independent third-party preclinical research service provider, we offer comprehensive animal model studies to support pharmaceutical, biotechnology, and academic clients in understanding human diseases and evaluating therapeutic interventions. Animal models are indispensable for investigating disease pathophysiology, testing drug efficacy and safety, and advancing translational medicine. Our accredited animal facility (AAALAC, IACUC) and experienced team develop and validate a wide range of disease models across multiple species, following GLP (Good Laboratory Practice) guidelines where required. This article outlines our animal model research capabilities – including scope, key study endpoints, and standard methodologies – to help you accelerate your drug discovery and development pipeline.

1. Our Research Scope for Animal Models of Human Diseases

We cover major human disease areas and a variety of animal species:

By disease area: Oncology (xenograft, syngeneic, patient‑derived xenograft – PDX, metastasis models); Inflammatory & autoimmune diseases (rheumatoid arthritis, inflammatory bowel disease, psoriasis, multiple sclerosis); Metabolic diseases (diabetes type 1 & 2, obesity, non‑alcoholic steatohepatitis – NASH, dyslipidemia); Cardiovascular diseases (atherosclerosis, hypertension, myocardial infarction, heart failure); Neurological & neurodegenerative diseases (Alzheimer’s, Parkinson’s, Huntington’s, stroke, epilepsy, multiple sclerosis); Infectious diseases (bacterial, viral, fungal – subject to biosafety level); Respiratory diseases (asthma, COPD, pulmonary fibrosis); Renal diseases (acute kidney injury, chronic kidney disease); Liver diseases (fibrosis, cirrhosis, acute liver injury); Ophthalmic diseases (retinal degeneration, glaucoma, uveitis); Orthopaedic diseases (osteoarthritis, osteoporosis, bone fracture healing).

By animal species: Rodents (mice – including transgenic, knock‑out, humanised; rats); Rabbits; Guinea pigs; Hamsters; Mini‑pigs; Non‑human primates (by arrangement and ethical compliance); Zebrafish (for early‑stage screening).

By study type: Efficacy studies (proof‑of‑concept, dose‑ranging); Pharmacokinetic/pharmacodynamic (PK/PD) studies; Safety & toxicology (acute, subchronic, chronic); Mechanism of action studies; Biomarker discovery; Imaging studies (MRI, PET, CT, bioluminescence).

2. Key Study Endpoints & Measurements We Perform

Our animal model services are organised by disease category and include both in vivo and ex vivo endpoints.

2.1 Oncology Models

Tumour growth inhibition (TGI) – subcutaneous, orthotopic, or metastatic models.
Tumour volume (caliper or IVIS bioluminescence) – time‑to‑endpoint, regression, stasis.
Survival benefit (Kaplan‑Meier).
Metastasis quantification (lung, liver, bone – ex vivo imaging or histology).
PDX model (patient‑derived xenograft) – preserves tumour heterogeneity and stroma.
Immune checkpoint inhibitor models (humanised mice with PD‑1, CTLA‑4).
Histopathology (necrosis, apoptosis, proliferation – Ki‑67).
Tumour biomarker analysis (IHC, Western blot, qPCR, ELISA).

2.2 Inflammatory & Autoimmune Models

Arthritis (collagen‑induced arthritis – CIA; adjuvant‑induced arthritis – AIA) – paw swelling, clinical score, histology of joints, inflammatory cytokines (IL‑1β, TNF‑α, IL‑6).
Inflammatory bowel disease (DSS‑induced colitis, TNBS‑induced colitis) – disease activity index (DAI), colon length, histological damage score.
Psoriasis (imiquimod‑induced, IL‑23 injection) – ear thickness, scaling, immune cell infiltration.
Multiple sclerosis (experimental autoimmune encephalomyelitis – EAE) – clinical score, spinal cord demyelination, inflammatory infiltrates.

2.3 Metabolic & NASH Models

Diabetes (STZ‑induced, high‑fat diet + STZ, db/db, ob/ob) – blood glucose, HbA1c, glucose tolerance test (GTT), insulin tolerance test (ITT), insulin levels.
NASH (high‑fat / high‑sucrose diet, choline‑deficient L‑amino acid defined – CDAA diet) – liver weight, serum ALT/AST, hepatic steatosis (Oil Red O), fibrosis (Sirius Red, collagen I), NAS score (NAFLD activity score).
Obesity (high‑fat diet induced) – body weight, fat mass (by NMR or dissection), food intake, metabolic cage analysis (O₂ consumption, CO₂ production, RER).

2.4 Cardiovascular Models

Atherosclerosis (ApoE⁻/⁻ or LDLR⁻/⁻ mice on high‑fat diet) – aortic plaque area (en face), lipid deposition, aortic root cross‑section, inflammatory markers.
Myocardial infarction (left anterior descending coronary artery ligation) – infarct size (TTC staining), echocardiography (EF, FS), cardiac enzymes (cTnI, CK‑MB).
Hypertension (spontaneously hypertensive rat – SHR; Angiotensin II infusion) – blood pressure (telemetry or tail‑cuff), vascular reactivity.

2.5 Neurological Models

Alzheimer’s disease (transgenic mice: APP/PS1, 5xFAD; streptozotocin‑induced) – Morris water maze (learning & memory), Y‑maze, novel object recognition, amyloid‑β plaque load (IHC), tau phosphorylation, microglial activation (Iba‑1).
Parkinson’s disease (MPTP, 6‑OHDA, α‑synuclein pre‑formed fibrils – PFFs) – rotarod, pole test, gait analysis, tyrosine hydroxylase (TH) positive neuron count, striatal dopamine levels (HPLC).
Ischemic stroke (middle cerebral artery occlusion – MCAO) – infarct volume (TTC or MRI), neurological deficit score, oedema measurement.
Epilepsy (pilocarpine, pentylenetetrazole – PTZ) – seizure latency, severity score, EEG recording.

2.6 Infectious Disease Models

Bacterial infection (S. aureus, E. coli, P. aeruginosa, M. tuberculosis) – bacterial load (CFU in tissue), survival, inflammatory response, histopathology.
Viral infection (influenza, RSV, SARS‑CoV‑2 – in appropriate BSL) – viral titre (TCID₅₀, qPCR), weight loss, lung pathology, cytokine storm.
Fungal infection (Candida albicans, Aspergillus) – fungal burden, organ fungal colony counts.

2.7 Respiratory Models

Asthma (ovalbumin – OVA; house dust mite – HDM) – airway hyperresponsiveness (Penh, resistance), bronchoalveolar lavage fluid (BALF) eosinophil count, IgE, Th2 cytokines (IL‑4, IL‑5, IL‑13), lung histology (Muc5ac, PAS).
COPD (elastase or cigarette smoke exposure) – pulmonary function, emphysema (mean linear intercept), airspace enlargement, BALF neutrophilia.
Pulmonary fibrosis (bleomycin‑induced) – Ashcroft score, hydroxyproline content, lung collagen (Sirius Red).

2.8 Renal & Hepatic Models

Acute kidney injury (cisplatin, ischaemia‑reperfusion, gentamicin) – serum creatinine, BUN, renal histology (tubular necrosis), KIM‑1, NGAL.
Chronic kidney disease (adenine diet, 5/6 nephrectomy) – proteinuria, glomerulosclerosis, tubulointerstitial fibrosis.
Acute liver injury (APAP, CCl₄, Con A) – ALT, AST, necrosis area, TUNEL, inflammatory infiltration.
Liver fibrosis (CCl₄ repeated, BDL – bile duct ligation) – collagen deposition (Sirius Red), hydroxyproline, α‑SMA.

3. Standard Research Methods & Endpoint Technologies We Apply

All studies are conducted in compliance with animal welfare regulations (AAALAC, IACUC) and, where required, GLP. Our laboratory is equipped with state‑of‑the‑art instrumentation for in vivo and ex vivo analysis.

3.1 In Vivo Techniques

Drug administration routes: oral gavage, intravenous, intraperitoneal, subcutaneous, intramuscular, intranasal, intrathecal.
Blood sampling (serial or terminal) – for PK/PD, clinical chemistry, haematology, cytokine analysis.
In vivo imaging (IVIS® spectrum) – bioluminescence (luciferase‑tagged tumours/cells), fluorescence (e.g., IRDye, GFP).
Telemetry – continuous monitoring of blood pressure, ECG, temperature, activity.
Behavioural tests: Morris water maze, Y‑maze, rotarod, open field, elevated plus maze, grip strength, tail suspension, hot plate.
Metabolic cages – oxygen consumption (VO₂), CO₂ production, respiratory exchange ratio (RER), food & water intake, locomotor activity.
Echocardiography (VisualSonics) – cardiac function (EF, FS, LV dimensions).

3.2 Ex Vivo & Molecular Analysis

Histopathology & immunohistochemistry (IHC) – formalin‑fixed, paraffin‑embedded (FFPE) or frozen sections, automated staining (e.g., Ki‑67, CD3, CD8, Iba‑1, GFAP, collagen).
Digital pathology (slide scanning) – whole‑slide imaging for quantification (HALO, Visiopharm).
Clinical chemistry & haematology – serum ALT, AST, BUN, creatinine, glucose, cholesterol, triglycerides, haematology analyser (WBC, RBC, platelets).
Cytokine/chemokine analysis – multiplex ELISA (Luminex, MSD), single‑plex ELISA (IL‑1β, TNF‑α, IL‑6, IFN‑γ, IL‑10).
qPCR / RT‑qPCR – gene expression of target genes (inflammatory, fibrotic, apoptotic).
Western blot – protein expression (e.g., phosphorylated signalling proteins, cleaved caspase‑3).
HPLC / LC‑MS – neurotransmitter levels (dopamine, serotonin, noradrenaline), drug concentrations.
Flow cytometry (immunophenotyping) – splenocytes, tumour‑infiltrating lymphocytes, BALF cells (CD4⁺, CD8⁺, Treg, MDSC).
MRI / micro‑CT – for bone, joint, brain, tumour, and cardiac imaging (by arrangement).

3.3 Standardised Model Induction & Validation Protocols

We follow published and internally validated protocols for each disease model, including positive controls (reference drugs) to ensure model responsiveness. For oncology: paclitaxel, doxorubicin, anti‑PD‑1; for arthritis: methotrexate, anti‑TNF; for NASH: obeticholic acid, elafibranor; for diabetes: metformin, insulin; for pain: gabapentin, morphine; for epilepsy: valproate, levetiracetam.

4. Why Choose Our Third‑Party Preclinical Animal Model Research Services?

As an independent contract research organisation (CRO) with deep expertise in animal models, we provide reliable, reproducible, and regulation‑ready data. Our advantages include:

AAALAC‑accredited animal facility – full IACUC oversight, strict environmental enrichment, and veterinary care.
GLP compliance – for safety and toxicology studies that support regulatory submissions (FDA, EMA, NMPA).
Wide model portfolio – over 100 validated disease models, including custom‑generated transgenic/humanised models.
Experienced team – board‑certified laboratory animal veterinarians, PhD scientists, and trained technicians.
Fast turnaround – typical efficacy studies (4‑8 weeks) with comprehensive endpoints; chronic studies (3‑12 months) scheduled accordingly.
Flexible engagement – full study design, execution, reporting, or modular services (e.g., only dosing and endpoint collection).
Detailed reporting – raw data, statistical analysis (GraphPad Prism), histology images, and interpretation ready for manuscripts or regulatory packages.
Confidentiality – full protection of your compound structures, study objectives, and proprietary data.

Whether you need to screen a library of compounds in an oncology model, validate a gene therapy in a neurodegenerative disease model, or perform regulatory‑compliant toxicology, our preclinical research team is ready to support your drug development journey.

Get Started with Your Animal Model Study

Contact our team with your disease area, desired animal model (species, strain, induction method), test articles, and required endpoints. We will provide a detailed study proposal, ethical approval documentation, animal acquisition and housing plan, and a complete budget. Let us help you bridge the gap between in vitro discovery and clinical success with scientifically rigorous, humane, and translational animal model research.

This article provides an overview of our preclinical animal model research capabilities. For specific models, study design, and pricing, please request a customised service proposal.